ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 30.6 | 23.2 | 9.8 |
| Other income | 0.7 | 0.1 | 0.1 |
| Total income | 31.3 | 23.3 | 9.8 |
| Profit before exceptional items & tax | 4.7 | 5.0 | 1.6 |
| Profit before tax | 4.7 | 5.0 | 1.6 |
| Net profit | 4.8 | 3.7 | 1.5 |
| Operating margin | 15.0% | 21.5% | 16.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +220.00% |
|---|---|
| Net profit, quarter on quarter | +29.70% |
| Revenue, year on year | +212.20% |
BSE results filing, NSE: GKSL. Figures extracted from the filing.
Gujarat Kidney and Super Speciality Ltd: key numbers
- Share price
- ₹156.37
- Market cap
- ₹1,233 Cr
- Revenue (annual)
- ₹82.01 Cr
- Net profit (annual)
- ₹15.50 Cr
- P/E (TTM)
- 64.9×Sector 54.5×
- Promoter holding
- 71.45%+0.00% QoQ
- FII holding
- 6.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Kidney and Super Speciality Ltd
All →Gujarat Kidney and Super Speciality Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹3,809L (+195% YoY), PAT ₹660L (17.3% margin). H1 FY27 revenue ₹7,238L, PAT ₹1,192L. Growth is acquisition-led, with Dubai entry.
Gujarat Kidney and Super Speciality Other Announcement
Gujarat Kidney filed Brickwork's monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation from the IPO fund-utilisation objects.
Gujarat Kidney and Super Speciality Q2 FY27 Results: Net Profit ₹6.6 Cr, Up 127.6% YoY
Gujarat Kidney and Super Speciality Ltd reported revenue from operations of ₹38.1 Cr (+195.3% YoY) and net profit of ₹6.6 Cr (+127.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹6.6 Cr · +127.6% YoY
Gujarat Kidney and Super Speciality Board Meeting Date
Gujarat Kidney will hold a board meeting on 04 Nov 2026 to consider unaudited quarterly results. The trading window closes from 01 Oct 2026.
Gujarat Kidney and Super Speciality Other Announcement
This is a routine quarterly shareholding pattern disclosure for the period ended September 30, 2026, filed under SEBI Regulation 31.
Gujarat Kidney and Super Speciality Annual General Meeting
Gujarat Kidney and Super Speciality Limited held its 7th Annual General Meeting on September 28, 2026. Shareholders approved financial statements, director appointments, and various regulatory borrowing and investment limits.